Ocugen to present modifier gene therapy platform at June investor conferences

OCUGEN INC

OCUGEN INC

OCGN

0.00
  • Ocugen will present its modifier gene therapy platform at Noble Capital Markets’ Emerging Growth Virtual Equity Conference on June 4, 2026.
  • Management will join a panel on inherited retinal diseases at Clinical Trials at the Summit 2026 in Las Vegas on June 13, 2026.
  • The company is scheduled to present at the BIO International Convention on June 23, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ocugen Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606020703PRIMZONEFULLFEED9730228) on June 02, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.